102 completed, 64 active not recruiting, 51 recruiting, 37 terminated. 166 Phase 2, 81 Phase 1, 50 Phase 3, 7 Early Phase 1, 3 Not applicable.
Follow Immunoglobulin G: new trials by email Literature Review of Immunoglobulin G trials Research Report on Immunoglobulin G
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Resectable Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-12-10 | 2026-06-10 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-09-17 |
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older Anakinra, Biospecimen Collection, Computed Tomography - Melanoma | Phase 1 | Not yet recruiting | University of Southern California | 40 | 2026-11-01 | 2026-09-24 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection - Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 87 | 2026-09-24 | 2026-10-20 |
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer Biopsy Procedure, Cisplatin, Computed Tomography - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 46 | 2026-05-29 | 2026-08-20 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-02 | 2026-04-06 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-10-22 |
| Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer Celecoxib, Durvalumab, Tremelimumab - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Emory University | 39 | 2026-01-02 | 2026-01-28 |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer Radiation Therapy, Pembrolizumab, Nab-paclitaxel - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 2 | Recruiting | Emory University | 29 | 2025-10-22 | 2026-04-17 |
| Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma all-trans retinoic acid, Cemiplimab, Computed Tomography - Leiomyosarcoma, Sarcoma | Phase 2 | Recruiting | Gabriel Tinoco | 16 | 2025-09-10 | 2026-10-01 |
| Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer Biospecimen Collection, Ceralasertib, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 630 | 2025-08-07 | 2026-09-21 |
| Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa Immunoglobulin G - Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Recruiting | M. Peter Marinkovich | 8 | 2025-08-04 | 2026-05-05 |
Showing 20 of 278. Sign in to see all of them.
Lung Neoplasms (29) · Ovarian Neoplasms (27) · Fallopian Tube Neoplasms (24) · Carcinoma, Non-Small-Cell Lung (23) · Colorectal Neoplasms (16) · Melanoma (14) · Carcinoma, Hepatocellular (12) · Carcinoma, Renal Cell (12) · Breast Neoplasms (11) · Glioblastoma (11) · Pancreatic Neoplasms (11) · Squamous Cell Carcinoma of Head and Neck (11) · Triple Negative Breast Neoplasms (10) · Neoplasm Metastasis (8) · Prostatic Neoplasms (8)
National Cancer Institute (NCI) (96) · M.D. Anderson Cancer Center (36) · Mayo Clinic (14) · University of Washington (13) · City of Hope Medical Center (10) · Emory University (7) · Jonsson Comprehensive Cancer Center (7) · Roswell Park Cancer Institute (7) · Academic and Community Cancer Research United (6) · Northwestern University (6) · SWOG Cancer Research Network (6) · OHSU Knight Cancer Institute (5) · Green Cross Corporation (4) · Fred Hutchinson Cancer Center (3) · NRG Oncology (3)
United States (256) · Canada (28) · Puerto Rico (11) · South Korea (8) · Australia (7) · New Zealand (5) · South Africa (5) · Japan (4) · Peru (4) · France (3) · Netherlands (3) · Spain (3) · Taiwan (3) · United Kingdom (3) · Bulgaria (2)
Emese Zsiros (4) · Vassiliki Papadimitrakopoulou (3) · Amir A Jazaeri (2) · Hope S Rugo (2) · Jing Zeng (2) · Joseph Curry, MD (2) · Mark Gilbert (2) · Michael Schweizer (2) · Nilofer S Azad (2) · Proclara Biosciences (2) · Ravi Salgia, MD (2) · Yinghong Wang (2) · A P Chen (1) · Aaron S Mansfield (1) · Aarti Bhatia (1)
PMID 37185961, PMID 24412910, PMID 32379297, PMID 34616010, PMID 35175355, PMID 11118469, PMID 12091876, PMID 12218188, PMID 15269160, PMID 1576319, PMID 15869455, PMID 15950727, PMID 16382236, PMID 1638557, PMID 1643631, PMID 17369569, PMID 19047298, PMID 19171714, PMID 19304016, PMID 19626208, PMID 19638464, PMID 20570856, PMID 20879881, PMID 21074057, PMID 21149662, PMID 21298742, PMID 21798350, PMID 21941283, PMID 21997132, PMID 22178121, PMID 22186141, PMID 22204724, PMID 22434180, PMID 22658127, PMID 22658128, PMID 22700000, PMID 22844125, PMID 22976553, PMID 23219660, PMID 23233715, PMID 23620404, PMID 23649004, PMID 23661160, PMID 23724867, PMID 24047116, PMID 24333097, PMID 24552317, PMID 24552320, PMID 24817603, PMID 24848257
U10CA180868 (29), U10CA180820 (18), U10CA027469 (13), U10CA180888 (11), U10CA180821 (10), P30CA033572 (9), P30CA015083 (8), P30CA138292 (7), U10CA021115 (7), U10CA021661 (7), P30CA060553 (6), U10CA031946 (6), P30CA015704 (4), P30CA016672 (4), U10CA032102 (4)